Asia-Pacific Musculoskeletal Diseases Market Research Report – Segmented By Type, Type Of Molecules & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)
The Asia Pacific Musculoskeletal Diseases Market is projected to grow at a prominent CAGR between 2022 and 2027. The Asia Pacific Musculoskeletal Diseases market is developing at a rapid pace.
People's growing awareness of the condition and treatment alternatives and their desire to live longer are all contributing to the market's rise. Similarly, providing advanced academic training to musculoskeletal disorder healthcare professionals, such as medical doctors, nurses, occupational therapists, physiotherapists, other allied healthcare professionals, community practitioners, and researchers, is expected to boost Asia Pacific's demand for musculoskeletal medicine and therapies.
Increased awareness of orthopedic devices, combined with technological improvements in orthopedic devices, may result in an unprecedented demand for physical and occupational therapies and medicines, as well as increased opportunities for healthcare suppliers and providers. In addition, the rise in the elderly population and an increase in the number of orthopedic physicians specializing in sports medicine, joint, hand, and spine replacement are driving the musculoskeletal medicine market.
Biologics and small molecules are the most common molecules employed in the development of musculoskeletal illness therapies. Muscle relaxants, anti-inflammatory medications, analgesics, immunosuppressives, antipyretics, and corticosteroids have emerged as the most commonly prescribed drugs for treating musculoskeletal ailments, with considerable growth projected in the following years. Treatment for musculoskeletal problems is carried out with the support of the most adaptable diagnostic imaging modalities, which can define a wide range of parameters in a living subject while also providing excellent spatial resolution. Numerous industry players have investigated this technique to acquire incredible precision through extensive product design and features innovation. Over the last few years, there have been several technological advancements in treating musculoskeletal diseases.
Heavy-duty drug use in the treatment of musculoskeletal pain is both insufficient and conflicting, and robust data is required to support clinical practice, which restricts the expansion of the musculoskeletal diseases market. In addition, the growing senior population boosted the demand for medical care and pushed up healthcare costs. As a result, there has been an increase in demand for pharmaceutical products, which has substantially impacted market growth throughout this time. The possible loss of revenue due to product delays and increased costs due to tight regulatory processes puts a strain on new product development investments, limiting the Asia pacific market for musculoskeletal diseases medications. Other properties, such as thermal-lability and sensitivity to microbial contamination, may limit biologic acceptance during the forecast period.
This research report on the APAC musculoskeletal diseases market has been segmented and sub-segmented into the following categories.
By Type:
- Rheumatoid Arthritis
- Osteoarthritis
- Osteoporosis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Fibromyalgia
- Others
By Type of Molecules:
- Biologics
- Small Molecules
By Treatment:
- Biologics
- Corticosteroids
- Parathyroid Hormone
- Protein Therapy
- Selective Estrogen Receptor Modulators
- Synthetic Bone Graft
- Composite Grafts
- Demineralized Bone Matrix
- BMPS
By Country:
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of APAC
During the forecast period, the Asia Pacific (APAC) market is expected to rise at a significant rate. Factors such as global industry players' increased attention on India and Japan and funding in China are expected to drive market expansion. The most common musculoskeletal diseases are rheumatoid arthritis, osteoporosis, osteoarthritis, psoriatic arthritis, fibromyalgia, and ankylosing spondylitis. Rheumatoid arthritis, which has a more significant prevalence rate than the others, has emerged as the market leader. Adults aged thirty to sixty years have the highest chronic inflammatory autoimmune illness prevalence. Researchers predict that the senior population will continue to grow during the forecast period and that this market is expected to continue to dominate.
KEY MARKET PLAYERS:
AbGenomics International, AB Sciences, Ablynx, Akron Molecules, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer, Eli Lilly, Adheron, Alder BioPharmaceuticals, Bioiberica, Bone Therapeutics, Edding Pharm, Boehringer Ingelheim, Can-Fite BioPharma, Celltrion, Celgene Corp., Cellular Biomedicine, ChemoCentryx, Cerapedics, Eupraxia Pharmaceuticals, and GlaxoSmithKline are the some of the key players in the Asia Pacific Musculoskeletal Diseases market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Rheumatoid Arthritis
5.1.3 Osteoarthritis
5.1.4 Osteoporosis
5.1.5 Psoriatic Arthritis
5.1.6 Ankylosing Spondylitis
5.1.7 Fibromyalgia
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Type
5.1.10 Market Attractiveness Analysis, By Type
5.1.11 Market Share Analysis, By Type
5.2 Type Of Molecules
5.2.1 Introduction
5.2.2 Biologics
5.2.3 Small Molecules
5.2.4 Y-o-Y Growth Analysis, By Type Of Molecules
5.2.5 Market Attractiveness Analysis, By Type Of Molecules
5.2.6 Market Share Analysis, By Type Of Molecules
5.3 Treatment
5.3.1 Introduction
5.3.2 Biologics
5.3.3 Corticosteroids
5.3.4 Parathyroid Hormone
5.3.5 Protein Therapy
5.3.6 Selective Estrogen Receptor Modulators
5.3.7 Synthetic Bone Graft
5.3.8 Composite Grafts
5.3.9 Demineralized Bone Matrix
5.3.10 BMPS
5.3.11 Y-o-Y Growth Analysis, By Treatment
5.3.12 Market Attractiveness Analysis, By Treatment
5.3.13 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Type Of Molecules
6.1.3.4 By Treatment
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Type Of Molecules
6.1.4.4 By Treatment
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Type Of Molecules
6.1.5.4 By Treatment
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson Private Limited
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Stryker Corporation
8.3 Akron Molecules
8.4 Adheron
8.5 Bone Therapeutics
8.6 Boehringer Ingelheim
8.7 ChemoCentryx
8.8 Daiichi Sankyo
8.9 GlaxoSmithKline
8.10 Eupraxia Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Asia Pacific Musculoskeletal Diseases Market, By Disease Type, From 2022 - 2027 (USD Million)
- Asia Pacific Rheumatoid Arthritis Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Osteoarthritis Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Osteoporosis Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Psoriatic Arthritis Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Ankylosing Spondylitis Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Fibromyalgia Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Others Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Musculoskeletal Diseases Market, By Type of molecules, From 2022 - 2027 (USD Million)
- Asia Pacific Biologics Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Small Molecules Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Market, By Region, From 2022 - 2027 (USD Million)
- Japan Musculoskeletal Diseases Market, By Disease Type, From 2022 - 2027 (USD Million)
- Japan Musculoskeletal Diseases Market, By Type of molecules, From 2022 - 2027 (USD Million)
- China Musculoskeletal Diseases Market, By Disease Type, From 2022 - 2027 (USD Million)
- China Musculoskeletal Diseases Market, By Type of molecules, From 2022 - 2027 (USD Million)
- India Musculoskeletal Diseases Market, By Disease Type, From 2022 - 2027 (USD Million)
- India Musculoskeletal Diseases Market, By Type of molecules, From 2022 - 2027 (USD Million)
- Australia Musculoskeletal Diseases Market, By Disease Type, From 2022 - 2027 (USD Million)
- Australia Musculoskeletal Diseases Market, By Type of molecules, From 2022 - 2027 (USD Million)
- South Korea Musculoskeletal Diseases Market, By Disease Type, From 2022 - 2027 (USD Million)
- South Korea Musculoskeletal Diseases Market, By Type of molecules, From 2022 - 2027 (USD Million)
Related Reports
ASK FOR CUSTOMIZATION
Talk to our analyst and get customised report done according to your research needs
INQUIRE FOR DISCOUNT
Check if you can avail any discount. Submit your details and our team will get back to you.
DOWNLOAD FREE SAMPLE
Request to avail a free sample report that reflects this market and its growth.
